These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19199360)

  • 21. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
    Eskens FA; Dumez H; Hoekstra R; Perschl A; Brindley C; Böttcher S; Wynendaele W; Drevs J; Verweij J; van Oosterom AT
    Eur J Cancer; 2003 May; 39(7):917-26. PubMed ID: 12706360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis.
    Bretschi M; Cheng C; Witt H; Dimitrakopoulou-Strauss A; Strauss LG; Semmler W; Bäuerle T
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):573-83. PubMed ID: 23229276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism.
    Elmghirbi R; Nagaraja TN; Brown SL; Panda S; Aryal MP; Keenan KA; Bagher-Ebadian H; Cabral G; Ewing JR
    Radiat Res; 2017 Jan; 187(1):79-88. PubMed ID: 28001908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
    Hariharan S; Gustafson D; Holden S; McConkey D; Davis D; Morrow M; Basche M; Gore L; Zang C; O'Bryant CL; Baron A; Gallemann D; Colevas D; Eckhardt SG
    Ann Oncol; 2007 Aug; 18(8):1400-7. PubMed ID: 17693653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.
    Ruffini F; Graziani G; Levati L; Tentori L; D'Atri S; Lacal PM
    Int J Cancer; 2015 Mar; 136(6):E545-58. PubMed ID: 25284767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The integrin antagonist, cilengitide, is a weak inhibitor of αIIbβ3 mediated platelet activation and inhibits platelet adhesion under flow.
    Meyer dos Santos S; Kuczka K; Picard-Willems B; Nelson K; Klinkhardt U; Harder S
    Platelets; 2015; 26(1):59-66. PubMed ID: 24433287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy of cilengitide with belotecan against experimental glioblastoma.
    Kim YH; Lee JK; Kim B; DeWitt JP; Lee JE; Han JH; Kim SK; Oh CW; Kim CY
    Int J Cancer; 2013 Aug; 133(3):749-56. PubMed ID: 23354807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrin control of the transforming growth factor-β pathway in glioblastoma.
    Roth P; Silginer M; Goodman SL; Hasenbach K; Thies S; Maurer G; Schraml P; Tabatabai G; Moch H; Tritschler I; Weller M
    Brain; 2013 Feb; 136(Pt 2):564-76. PubMed ID: 23378223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is neuroglial antigen 2 a potential contributor to cilengitide response in glioblastoma?
    Nalkiran HS; McDonald KL
    J Cancer Res Ther; 2017; 13(2):329-336. PubMed ID: 28643756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.
    Abdollahi A; Griggs DW; Zieher H; Roth A; Lipson KE; Saffrich R; Gröne HJ; Hallahan DE; Reisfeld RA; Debus J; Niethammer AG; Huber PE
    Clin Cancer Res; 2005 Sep; 11(17):6270-9. PubMed ID: 16144931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
    Beekman KW; Colevas AD; Cooney K; Dipaola R; Dunn RL; Gross M; Keller ET; Pienta KJ; Ryan CJ; Smith D; Hussain M
    Clin Genitourin Cancer; 2006 Mar; 4(4):299-302. PubMed ID: 16729916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of cilengitide in osteoclast maturation and behavior.
    Chillà A; Bianconi D; Geetha N; Dorda A; Poettler M; Unseld M; Sykoutri D; Redlich K; Zielinski CC; Prager GW
    Exp Cell Res; 2015 Sep; 337(1):68-75. PubMed ID: 26209605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.
    Monferran S; Skuli N; Delmas C; Favre G; Bonnet J; Cohen-Jonathan-Moyal E; Toulas C
    Int J Cancer; 2008 Jul; 123(2):357-364. PubMed ID: 18464290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glioblastoma cells block radiation-induced programmed cell death of endothelial cells.
    Brown CK; Khodarev NN; Yu J; Moo-Young T; Labay E; Darga TE; Posner MC; Weichselbaum RR; Mauceri HJ
    FEBS Lett; 2004 May; 565(1-3):167-70. PubMed ID: 15135073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
    Reardon DA; Neyns B; Weller M; Tonn JC; Nabors LB; Stupp R
    Future Oncol; 2011 Mar; 7(3):339-54. PubMed ID: 21417900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats.
    Ning S; Tian J; Marshall DJ; Knox SJ
    Cancer Res; 2010 Oct; 70(19):7591-9. PubMed ID: 20841470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
    Scaringi C; Minniti G; Caporello P; Enrici RM
    Anticancer Res; 2012 Oct; 32(10):4213-23. PubMed ID: 23060541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
    Tentori L; Dorio AS; Muzi A; Lacal PM; Ruffini F; Navarra P; Graziani G
    Oncol Rep; 2008 Apr; 19(4):1039-43. PubMed ID: 18357394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.
    Onishi M; Ichikawa T; Kurozumi K; Fujii K; Yoshida K; Inoue S; Michiue H; Chiocca EA; Kaur B; Date I
    Neuropathology; 2013 Apr; 33(2):162-74. PubMed ID: 22989076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.